

Exhibitor Spotlight

Schedule

Join your colleagues for the latest advances in nephrology practices, products, services, and technologies presented in three theaters on the exhibit hall floor (no continuing education credit). Seating is limited and available on a first-come, first-served basis. Enter at Exhibit Hall D.

The 10:00 a.m. presentations include breakfast. All other presentations include lunch.

Thursday, November 6

10:00-10:45 a.m.

Theater 1

HighVolumeHDF: The Next Standard of Care for US Patients - Evidence and Practical Use

Presented by



11:00-11:45 a.m.

Theater 2

Global Pathways to Home: Strategies for Success

Presented by



11:30 a.m.-12:15 p.m.

Theater 3

Expert Perspectives and Patient Experiences: Upgrading to a Stronger Foundation in IgA Nephropathy

Presented by



12:00-12:45 p.m.

Theater 1

Advancing Care in Lupus Nephritis: Exploring the Evolving Landscape

Presented by



12:30-1:15 p.m.

Theater 2

Houston, We Have a Solution: Integrating Genetics into Clinical Practice

Presented by



1:00-1:45 p.m.

Theater 3

B-cell Modulation in IgA Nephrology and a Patient Case Study

Presented by



Friday, November 7

10:00-10:45 a.m.

Theater 1

Decoding a Silent Threat: Aldosterone's Impact on Hypertension and Cardiovascular and Renal Morbidity

Presented by



11:00-11:45 a.m.

Theater 2

Expanding Perspectives in Hyperphosphatemia Treatment; A Different Approach

Presented by



11:30 a.m.-12:15 p.m.

Theater 3

IgA Nephropathy Paradigm Shift: KDIGO Guidelines and the Centrality of B Cells

Presented by



Friday, November 7 (Continued)

12:00-12:45 p.m.

Theater 1

Hypoxia-Inducible Factor Activation & Erythropoietic Effects in Anemia due to CKD

Presented by



12:30-1:15 p.m.

Theater 2

Navigating the Crossroads of IgAN: 2 Distinct Paths to Reducing Proteinuria

Presented by



1:00-1:45 p.m.

Theater 3

Targeting IgAN Early: Considerations for Adding Potentially Disease Modifying Therapy to Frontline Treatment

Presented by



Saturday, November 8

10:00-10:45 a.m.

Theater 1

Optimizing Transitions of Care in Kidney Transplantation: The Role of Envarsus XR®

Presented by



11:00-11:45 a.m.

Theater 2

Jardiance® (empagliflozin) tablets: Expert Perspectives on Clinical Trial Data and Approved Indications

Presented by



11:30 a.m.-12:15 p.m.

Theater 3

Taking a Different Direction in the Treatment of Primary Hyperoxaluria Type 1 (PH1)

Presented by



12:00-12:45 p.m.

Theater 1

Role of CD38+ Cells in Immune-Mediated Kidney Disease

Presented by



12:30-1:15 p.m.

Theater 2

Translating KDIGO Guidelines into Therapeutic Goals in IgA Nephropathy

Presented by



1:00-1:45 p.m.

Theater 3

DefenCath® Indication, Use and Navigating Reimbursement Across Settings of Care

Presented by

